NCT01340183暂停1 期
A Phase I, Single-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics in Intravenous AZD5099 After Single Ascending Doses in Healthy Male and Female Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 暂停
- 发起方
- AstraZeneca
- 入组人数
- 80
- 试验地点
- 1
- 主要终点
- To assess the safety and tolerability of AZD5099
研究概览
简要总结
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of the drug AZD5099 after intravenous administration of single doses in healthy volunteers. The results from this study will form the basis for decisions regarding the future development of AZD5099 as a novel antibiotic for the treatment of serious infections in humans.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Provision of signed and dated, written informed consent prior to any study-specific procedures including the genetic sampling
- •Healthy male and female (with nonchildbearing potential) volunteers aged 18 to 55 years (inclusive) with suitable veins for cannulation or repeated venipuncture
- •Females must have a negative pregnancy test at screening and on admission to the unit, must not be lactating and must be of nonchildbearing potential, confirmed at screening by fulfilling 1 of the following criteria:
- •Postmenopausal, defined as amenorrhea for at least 12 months following cessation of all exogenous hormonal treatments and with follicle stimulating hormone (FSH) levels within the laboratory-defined post-menopausal range
- •Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy but not tubal ligation
- •Male volunteers should be willing to use barrier contraception, ie, condoms, from the day of dosing until at least 3 months after dosing with the investigational product
- •Have a body mass index (BMI) between 18 and 30.5 kg/m2 and weigh at least 50 kg and no more than 100 kg inclusive
排除标准
- •History of any clinically important disease or disorder which, in the opinion of the Investigator, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study
- •History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs
- •Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of investigational product
- •History of gastrointestinal ulcer disease, inflammatory bowel disease, indigestion symptoms >3 times a week, or blood in stool in previous 6 months not related to anal trauma
- •For male volunteers any history of sexual dysfunction or impotence as judged by the Investigator
研究组 & 干预措施
AZD5099
Experimental
IV Dose
干预措施: AZD5099 (Drug)
Placebo
Placebo Comparator
IV Dose
干预措施: Placebo (Drug)
结局指标
主要结局
To assess the safety and tolerability of AZD5099
时间窗: Ongoing throughout the study from consent (up to 28 days prior to dosing) through withdrawal or completion (up to 10 days after discharge).
To assess the safety and tolerability of AZD5099 by documenting: 1) the incidence and severity of adverse events, 2) abnormalities and time matched comparison from Day -1 to Day 1 of core body temperature and vital sign assessments, 3) electrocardiograms (ECGs), 4) telemetry, 5) clinical laboratory assessments, 6) physical examinations, and 7) withdrawals.
次要结局
- Blood samples to characterize the pharmacokinetics of AZD5099, 48 hour(48 hour post start of infusion)
- Blood samples to characterize the pharmacokinetics of AZD5099, 72 hour(72 hour post start of infusion)
- Blood samples to characterize the pharmacokinetics of AZD5099, 10 hour(10 hour post start of infusion)
- Blood samples to characterize the pharmacokinetics of AZD5099, 12 hour(12 hour post start of infusion)
- Blood samples to characterize the pharmacokinetics of AZD5099, 8 hour(8 hour post start of infusion)
- Blood samples to characterize the pharmacokinetics of AZD5099, 24 hour(24 hour post start of infusion)
- Blood samples to characterize the pharmacokinetics of AZD5099, 36 hour(36 hour post start of infusion)
- Blood samples to characterize the pharmacokinetics of AZD5099, pre-dose(Pre-dose)
- Blood samples to characterize the pharmacokinetics of AZD5099, 15 min(15 minutes post start of infusion)
- Blood samples to characterize the pharmacokinetics of AZD5099, 30 min(30 minutes post start of infusion)
- Blood samples to characterize the pharmacokinetics of AZD5099, 1 hour(1 hour post start of infusion)
- Blood samples to characterize the pharmacokinetics of AZD5099, 2 hour(2 hour post start of infusion)
- Blood samples to characterize the pharmacokinetics of AZD5099, 2.5 hour(2.5 hour post start of infusion)
- Blood samples to characterize the pharmacokinetics of AZD5099, 3 hour(3 hour post start of infusion)
- Blood samples to characterize the pharmacokinetics of AZD5099, 4 hour(4 hour post start of infusion)
- Blood samples to characterize the pharmacokinetics of AZD5099, 5 hour(5 hour post start of infusion)
- Blood samples to characterize the pharmacokinetics of AZD5099, 6 hour(6 hour post start of infusion)
- Blood samples to characterize the pharmacokinetics of AZD5099, 96 hour(96 hour post start of infusion)
- Blood samples to characterize the pharmacokinetics of AZD5099, 120 hour(120 hour post start of infusion)
- Urine samples to characterize the pharmacokinetics of AZD5099, pre-dose(Between -12 to 0 hours)
- Urine samples to characterize the pharmacokinetics of AZD5099, 0-4 hours(Between 0 - 4 hours post start of infusion)
- Urine samples to characterize the pharmacokinetics of AZD5099, 4-8 hours(Between 4 - 8 hours post start of infusion)
- Urine samples to characterize the pharmacokinetics of AZD5099, 8-12 hours(Between 8 - 12 hours post start of infusion)
- Urine samples to characterize the pharmacokinetics of AZD5099, 12-24 hours(Between 12 - 24 hours post start of infusion)
- Urine samples to characterize the pharmacokinetics of AZD5099, 24-48 hours(Between 24 - 48 hours post start of infusion)
- Urine samples to characterize the pharmacokinetics of AZD5099, 48-72 hours(Between 48 - 72 hours post start of infusion)
- Urine samples to characterize the pharmacokinetics of AZD5099, 72-96 hours(Between 72 - 96 hours post start of infusion)
- Urine samples to characterize the pharmacokinetics of AZD5099, 96-120 hours(Between 96 - 120 hours post start of infusion)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Inhaled AZD8683HealthyNCT01419600AstraZeneca38
已完成
1 期
To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Administration of AZD8329OverweightHealthyMaleNCT01207089AstraZeneca45
已完成
1 期
AZD9164 Single Ascending Dose Study in Healthy Male SubjectsHealthyNCT00847249AstraZeneca65
已完成
1 期
AZD6088 Single Ascending Dose StudyHealthy VolunteersNCT00931541AstraZeneca35
已完成
1 期
AZD5423 Single Ascending Dose StudyHealthy VolunteersNCT00963183AstraZeneca72